The story of the blue pill offers a intricate case study for analysts eyeing pharma. While early sales were remarkable, present patent expiry and the emergence of cheaper versions have significantly impacted https://umarbvja859150.full-design.com/the-blue-pill-and-big-pharma-a-risky-bet-83627214